Share-based Payment Arrangement, Expense of Forte Biosciences, Inc. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Forte Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • Forte Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,479,000, a 87% increase year-over-year.
  • Forte Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $5,291,000, a 66% increase year-over-year.
  • Forte Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $3,095,000, a 5.8% decline from 2023.
  • Forte Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,284,000, a 18% decline from 2022.
  • Forte Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4,015,000, a 4.7% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Forte Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $5,291,000 $1,479,000 +$688,000 +87% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $4,603,000 $1,495,000 +$693,000 +86% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $3,910,000 $1,620,000 +$815,000 +101% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $3,095,000 $697,000 -$83,000 -11% 01 Oct 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
Q3 2024 $3,178,000 $791,000 +$19,000 +2.5% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $3,159,000 $802,000 -$53,000 -6.2% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $3,212,000 $805,000 -$72,000 -8.2% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $3,284,000 $780,000 -$80,000 -9.3% 01 Oct 2023 31 Dec 2023 10-K 28 Mar 2025 2024 FY
Q3 2023 $3,364,000 $772,000 -$134,000 -15% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $3,498,000 $855,000 -$339,000 -28% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $3,837,000 $877,000 -$178,000 -17% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $4,015,000 $860,000 -$378,000 -31% 01 Oct 2022 31 Dec 2022 10-K 18 Mar 2024 2023 FY
Q3 2022 $4,393,000 $906,000 -$567,000 -38% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $4,960,000 $1,194,000 +$186,000 +18% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $4,774,000 $1,055,000 +$560,000 +113% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $4,214,000 $1,238,000 +$683,000 +123% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 $3,531,000 $1,473,000 +$1,098,000 +293% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $2,433,000 $1,008,000 +$984,000 +4100% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $1,449,000 $495,000 +$493,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $956,000 $555,000 +$3,521,000 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $2,565,000 $375,000 +$373,000 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $2,938,000 $24,000 -$976,000 -98% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $1,962,000 $2,000* -$1,998,000 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $36,000 $2,966,000 -$4,716,000 -269% 01 Oct 2019 31 Dec 2019 10-K 16 Mar 2021 2020 FY
Q3 2019 $4,752,000 $2,000* -$1,925,000 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $6,677,000 $1,000,000 -$672,000 -40% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $7,349,000 $2,000,000 +$479,000 +31% 01 Jan 2019 31 Mar 2019 10-Q 23 Apr 2020 2020 Q1
Q4 2018 $6,870,000 $1,750,000 +$375,000 +27% 01 Oct 2018 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q3 2018 $6,495,000 $1,927,000 +$436,000 +29% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $6,059,000 $1,672,000 +$616,000 +58% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $5,443,000 $1,521,000 +$992,000 +188% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $4,451,000 $1,375,000 +$972,000 +241% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
Q3 2017 $3,479,000 $1,491,000 +$1,175,000 +372% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $2,304,000 $1,056,000 +$717,000 +212% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $1,587,000 $529,000 +$264,000 +100% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018 2018 Q1
Q4 2016 $1,323,000 $403,000 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
Q3 2016 $316,000 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $339,000 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $265,000 01 Jan 2016 31 Mar 2016 10-Q 23 May 2017 2017 Q1

Forte Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,095,000 -$189,000 -5.8% 01 Jan 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
2023 $3,284,000 -$731,000 -18% 01 Jan 2023 31 Dec 2023 10-K 28 Mar 2025 2024 FY
2022 $4,015,000 -$199,000 -4.7% 01 Jan 2022 31 Dec 2022 10-K 18 Mar 2024 2023 FY
2021 $4,214,000 +$3,258,000 +341% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $956,000 +$920,000 +2556% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
2019 $36,000 -$6,834,000 -99% 01 Jan 2019 31 Dec 2019 10-K 16 Mar 2021 2020 FY
2018 $6,870,000 +$2,419,000 +54% 01 Jan 2018 31 Dec 2018 10-K 27 Feb 2020 2019 FY
2017 $4,451,000 +$3,128,000 +236% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
2016 $1,323,000 +$261,000 +25% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
2015 $1,062,000 01 Jan 2015 31 Dec 2015 10-K 09 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.